Kate Gelperin
Overview
Explore the profile of Kate Gelperin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bird S, Gelperin K, Smith E, Jung T, Lyu H, Thompson A, et al.
Ann Intern Med
. 2024 Nov;
178(1):29-38.
PMID: 39556837
Background: There is a paucity of data on treatment of osteoporosis in patients with advanced chronic kidney disease (CKD). Objective: To assess the risk for emergently treated hypocalcemia with denosumab...
2.
Bird S, Gelperin K, Graham D
JAMA
. 2024 May;
331(21):1865-1866.
PMID: 38717783
No abstract available.
3.
Bird S, Smith E, Gelperin K, Jung T, Thompson A, Kambhampati R, et al.
JAMA
. 2024 Jan;
331(6):491-499.
PMID: 38241060
Importance: Dialysis-dependent patients experience high rates of morbidity from fractures, yet little evidence is available on optimal treatment strategies. Chronic kidney disease-mineral and bone disorder is nearly universal in dialysis-dependent...
4.
Winterstein A, Thai T, Nduaguba S, Smolinski N, Wang X, Sahin L, et al.
Am J Obstet Gynecol
. 2022 Oct;
228(4):465.e1-465.e11.
PMID: 36241080
Background: Concerns have been raised about prenatal exposure to magnetic resonance imaging with gadolinium-based contrast agents because of nonclinical findings of gadolinium retention in fetal tissue and 1 population-based study...
5.
Bird S, Tian F, Flowers N, Przepiorka D, Wang R, Jung T, et al.
JAMA Oncol
. 2019 Dec;
6(2):248-254.
PMID: 31855259
Importance: Idelalisib (IDEL) is approved as monotherapy in relapsed follicular lymphoma (FL) and with rituximab (IDEL+R) for relapsed chronic lymphocytic leukemia (CLL). Toxic effects can be severe and treatment-limiting. Outcomes...
6.
Bird S, Gelperin K, Sahin L, Bleich K, Fazio-Eynullayeva E, Woods C, et al.
Radiology
. 2019 Aug;
293(1):193-200.
PMID: 31429682
BackgroundThe safety of gadolinium-based contrast agent (GBCA) exposure during pregnancy has not been established, and the use of GBCAs during pregnancy is not recommended unless it is essential to the...
7.
Bird S, Swain R, Tian F, Okusanya O, Waldron P, Khurana M, et al.
Lancet Child Adolesc Health
. 2018 Nov;
3(1):15-22.
PMID: 30455109
Background: Serious and fatal deferasirox-induced kidney injury has been reported in paediatric patients. This study aimed to investigate the effects of deferasirox dose and serum ferritin concentrations on kidney function...
8.
Bird S, Toh S, Sahin L, Andrade S, Gelperin K, Taylor L, et al.
Am J Epidemiol
. 2018 Oct;
188(2):418-425.
PMID: 30321259
Letrozole is an aromatase inhibitor that has an unapproved use for ovulation induction with infertility. Because of the proximity of this use to conception, we selected letrozole to study the...
9.
Illoh O, Toh S, Andrade S, Hampp C, Sahin L, Gelperin K, et al.
Pharmacoepidemiol Drug Saf
. 2018 Mar;
27(6):604-611.
PMID: 29516585
Purpose: To describe the utilization of drugs with pregnancy exposure registries by trimester during pregnancy, in comparison with matched nonpregnant episodes and a pre-pregnancy period. Methods: We identified live-born deliveries...
10.
Bird S, Gelperin K, Taylor L, Sahin L, Hammad H, Andrade S, et al.
Drug Saf
. 2017 Aug;
41(1):87-94.
PMID: 28840499
Introduction: Pregnancy registries and spontaneous reports are essential pharmacovigilance tools to evaluate drug safety during pregnancy. Objectives: The aim of this study was to evaluate postmarket capture of exposed pregnancies....